Tag:
Zaltrap
Latest Headlines
Latest Headlines
Sanofi colorectal cancer contender Zaltrap suffers a PhIII trial setback
Sanofi and Regeneron's opened their update on the cancer drug Zaltrap (aflibercept) on a sweet note: The FDA has granted a priority review of their NDA for colorectal cancer.
Sanofi, Regeneron buoyed by Ph3 colon cancer success for aflibercept
Just weeks after Sanofi-Aventis and Regeneron ( $REGN ) reported that their cancer drug aflibercept stumbled in a late-stage study of non-small cell lung cancer, researchers gave a thumbs-up to their
